Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UWD-CD19 in Refractory and Relapsed B-Cell Tumors
NCT06662227Phase 1Suspended
- Sponsor
- Wondercel Therapeutics
- Start
- Oct 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UWD-19 in B cell lymphoma, B-cell leukemia (BCL) and B-cell malignancy, sponsored by Wondercel Therapeutics. Primary endpoints: Maximum Tolerated Dose at 1 month, Dose-Limiting Toxicities at 1 month and 1 more. Started Oct 2024; status: suspended.
02
Drugs
UWD-19
03
Conditions
B cell lymphomaB-cell leukemia (BCL)B-cell malignancy
Beyond the preview
Go deeper on NCT06662227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662227.